FDA Reaffirms HCT/P E-Registration Rules for Tissue Establishments

For HCT/P manufacturers operating under section 361 of the Public Health Service Act, FDA's registration framework carries compliance obligations that run on fixed calendar deadlines, and missing them is not a minor administrative lapse. Under 21 CFR Part 1271, establishments must register and list their human cells, tissues, and cellular and tissue-based products within five days of beginning operation, with annual updates required each December.

The 2016 final rule, published in the Federal Register on August 31, 2016 (81 FR 60170), mandated electronic submission of establishment registration and product listing information via FDA's eHCTERS platform, replacing paper-based processes. Waivers from the electronic submission requirement remain available under §1271.23, but establishments must proactively request them. QA directors should note that FDA acceptance of a registration does not constitute a compliance determination or signal product approval, as explicitly stated under §1271.27(b).

Amendment obligations add another layer of operational discipline. Any change in ownership, facility location, or U.S. agent contact details triggers a 30-calendar-day amendment window. Product listing changes described under §1271.25(c)(1) through (4) must be submitted at the time of change or by the first occurring June or December deadline. For multi-site operations or those with active foreign supplier relationships, maintaining accurate U.S. agent records in eHCTERS is a standing compliance task, not a periodic one.

Foreign establishments importing or offering HCT/Ps into the U.S. carry the same registration obligations and must additionally provide U.S. agent information and identify known importers. Regulatory affairs leads managing cross-border supply chains should confirm that foreign partners are registered and that agent records reflect current contacts.

The regulatory pathway bifurcation introduced by the 2016 rule remains operationally significant: establishments manufacturing HCT/Ps regulated as drugs, devices, or biological products under section 351 of the PHS Act or the FD&C Act must register under 21 CFR Part 207 or 807, not Part 1271. Products under active IND (21 CFR Part 312) or IDE (21 CFR Part 812) are exempt from Part 207 or 807 registration until marketing authorization is granted, providing a defined but time-limited window for investigational programs.

With December annual update deadlines recurring each year, tissue establishment compliance teams should treat eHCTERS access and amendment workflows as standing SOPs rather than reactive tasks.

Source: FDA / What's New Vaccines Blood Biologics RSS Feed, August 17, 2026.